Other languages Arbutus Biopharma Corporation

Equities

ABUS

CA03879J1003

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
2.72 ^USD	-1.09%		-0.37%	+8.80%

Apr. 05	Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	MT
Apr. 04	Moderna Suffers Setback in Lawsuit by Arbutus	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	Apr. 05
Moderna Suffers Setback in Lawsuit by Arbutus	Apr. 04
Moderna shares fall after judge sides with Arbutus in patent fight	Apr. 03
Arbutus Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29
Arbutus Biopharma, Inc. Announces Clinical Development Milestones to Advance Its HBV Pipeline	Jan. 08
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD	Nov. 09
Arbutus Biopharma Posts Q3 Net Loss, Lower Revenue; CEO to Retire, 24% Research Staff Cut	Nov. 07
Arbutus Biopharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
Arbutus Biopharma Corporation Announces CEO Changes	Nov. 07
Arbutus Biopharma Corporation Announces President Changes	Nov. 07
Arbutus Biopharma Discontinues Coronavirus, Oral RNA Destabilizer Programs, Focuses on Hepatitis B Virus Treatment Assets	23-09-11
Arbutus Biopharma Corporation Announces Pipeline Updates and Dosing of First Subject in Phase 1a/1b Clinical Trial with AB-101	23-09-11
Arbutus Biopharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
Arbutus Biopharma Corporation Announces the Appointment of Melissa V. Rewolinski to Its Board of Directors	23-07-12
Arbutus Biopharma Promotes Dr. Karen Sims to Chief Medical Officer, Hires Christopher Naftzger as Chief Compliance Officer	23-07-10
Arbutus Biopharma Corporation Appoints Two New Executives	23-07-10
Arbutus' Phase 2a Trial Shows AB-729 Plus Pegylated Interferon Alfa-2a Well Tolerated in Chronic Hepatitis B Virus Patients	23-06-21
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2A Triple Combination Clinical Trial That Includes A Pd-1 Monoclonal Antibody	23-06-21
Arbutus Presents Preliminary Ab-729 and Pegylated Interferon Alfa-2A Combination Data At the Easl Congress 2023	23-06-21
Arbutus Biopharma Corporation to Present AB-729 and AB-836 Data at EASL Congress 2023	23-06-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Arbutus Biopharma Corporation

Equities

ABUS

CA03879J1003

Other languages

Filters